» Articles » PMID: 28531119

Quality Attributes and In Vitro Bioequivalence of Different Brands of Amoxicillin Trihydrate Tablets

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2017 May 23
PMID 28531119
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Bacterial resistance and antibiotic drug effectiveness can be related to administering generic products with a subtherapeutic dose or poor in vivo drug release. The aim of this study was to investigate whether locally marketed amoxicillin tablets have the required chemical and physical attributes, including in vitro bioequivalence performance. Five generic products (T1, T2, T3, T4, and T5) containing combination of amoxicillin trihydrate and potassium clavulanate as 1 g strength present in immediate release tablets were compared to the reference listed drug product Augmentin® (R) for weight variation, friability, resistance to crushing, and chemical content of amoxicillin. Difference (ƒ1) and similarity (ƒ2) factors were calculated to assess in vitro bioequivalence requirements. The tablets from different products have shown compliance with the pharmacopeial requirements of the performed tests. The measured resistance to crushing of tablets did not influence the dissolution time. Three generic products released more than 85% of amoxicillin by the first 15 min as did the reference product and were considered as bioequivalent products. T1 and T4 had ƒ1 values of 16.5% and 25.4% respectively and their ƒ2 values were 44.5 and 34.6 respectively, indicating failure to meet in vitro bioequivalence requirements. Tablet formulations can play an important role in achieving bioequivalence. Independent investigations such as this study serve as an important tool to reveal possible inferior or noncompliant products that may find their way to the market.

Citing Articles

Post-marketing quality surveillance of selected antibacterial agents marketed in porous borders; the case of Ethiopia-Sudan-Eritrea border.

Denekew T, Eticha T, Teshome Y, Endeshaw S, Ashenef A PLoS One. 2024; 19(8):e0308223.

PMID: 39133679 PMC: 11318851. DOI: 10.1371/journal.pone.0308223.


Quality Assessment of Selected Essential Antimicrobial Drugs from Drug Retail Outlets of Selected Cities in Eastern Ethiopia.

Anjulo H, Birhane W, Hymete A, Ashenef A Am J Trop Med Hyg. 2024; 110(3):596-608.

PMID: 38350137 PMC: 10919192. DOI: 10.4269/ajtmh.23-0536.


In vitro comparative quality evaluation of different brands of carbamazepine tablets commercially available in Dessie town, Northeast Ethiopia.

Asrade B, Tessema E, Tarekegn A BMC Pharmacol Toxicol. 2023; 24(1):35.

PMID: 37231520 PMC: 10210453. DOI: 10.1186/s40360-023-00670-1.


Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes.

Novac M, Musuc A, Ozon E, Sarbu I, Mitu M, Rusu A Molecules. 2022; 27(6).

PMID: 35335371 PMC: 8955142. DOI: 10.3390/molecules27062012.


In vitro Comparative Quality Assessment of Different Brands of Furosemide Tablets Marketed in Northwest Ethiopia.

Abebe S, Ketema G, Kassahun H Drug Des Devel Ther. 2020; 14:5119-5128.

PMID: 33262573 PMC: 7700078. DOI: 10.2147/DDDT.S280203.


References
1.
Andrajati R, Tilaqza A, Supardi S . Factors related to rational antibiotic prescriptions in community health centers in Depok City, Indonesia. J Infect Public Health. 2016; 10(1):41-48. DOI: 10.1016/j.jiph.2016.01.012. View

2.
Dash S, Murthy P, Nath L, Chowdhury P . Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010; 67(3):217-23. View

3.
Riaz H, Krasuski R . Should Physicians be Encouraged to use Generic Names and to Prescribe Generic Drugs?. Am J Cardiol. 2016; 117(11):1851-2. DOI: 10.1016/j.amjcard.2016.03.023. View

4.
van den Bergh J, Bouts M, van der Veer E, van der Velde R, Janssen M, Geusens P . Comparing tolerability and efficacy of generic versus brand alendronate: a randomized clinical study in postmenopausal women with a recent fracture. PLoS One. 2013; 8(10):e78153. PMC: 3804551. DOI: 10.1371/journal.pone.0078153. View

5.
Tsume Y, Amidon G . The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation. Mol Pharm. 2010; 7(4):1235-43. DOI: 10.1021/mp100053q. View